We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after August 19, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
BIOMARKERS FOR KAWASAKI DISEASE
METHOD OF TREATING ALVEOLAR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES
METHOD OF INTRODUCING NUCLEIC ACID INTO PLANT CELLS
EARLY DETECTION OF TUBERCULOSIS TREATMENT RESPONSE
GLYCOFORM DETECTION METHOD AND GLYCOFORM DETECTION DEVICE
ANTHRACNOSE RESISTANCE-ASSOCIATED MARKER FOR PLANT OF GENUS FRAGARIA, AND USE THEREOF
CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT